메뉴 건너뛰기




Volumn 4, Issue 4, 2007, Pages 211-217

TOR (target of rapamycin) as an anti-cancer target

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AP 23573; AROMATASE INHIBITOR; CYCLIN D1; CYCLOSPORIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EVEROLIMUS; FK 506 BINDING PROTEIN; FLUORODEOXYGLUCOSE F 18; GEFITINIB; INITIATION FACTOR 4E BINDING PROTEIN 1; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; SOMATOMEDIN C RECEPTOR; SUNITINIB; TACROLIMUS; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN;

EID: 46749089971     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2008.04.004     Document Type: Review
Times cited : (3)

References (54)
  • 1
    • 24944480788 scopus 로고    scopus 로고
    • The Akt-mTOR tango and its relevance to cancer
    • Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 8 (2005) 179-183
    • (2005) Cancer Cell , vol.8 , pp. 179-183
    • Hay, N.1
  • 2
    • 33746637660 scopus 로고    scopus 로고
    • Current development of mTOR inhibitors as anticancer agents
    • Faivre S. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 5 (2006) 671-688
    • (2006) Nat. Rev. Drug Discov. , vol.5 , pp. 671-688
    • Faivre, S.1
  • 3
    • 34347220473 scopus 로고    scopus 로고
    • Defining the role of mTOR in cancer
    • Guertin D.A. Defining the role of mTOR in cancer. Cancer Cell 12 (2007) 9-22
    • (2007) Cancer Cell , vol.12 , pp. 9-22
    • Guertin, D.A.1
  • 4
    • 33750058023 scopus 로고    scopus 로고
    • Upstream of the mammalian target of rapamycin: do all roads pass trough mTOR?
    • Corradetti M.N. Upstream of the mammalian target of rapamycin: do all roads pass trough mTOR?. Oncogene 25 (2006) 6347-6360
    • (2006) Oncogene , vol.25 , pp. 6347-6360
    • Corradetti, M.N.1
  • 5
    • 3342895823 scopus 로고    scopus 로고
    • Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
    • Sarbassov D.D. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 14 (2004) 1296-1302
    • (2004) Curr. Biol. , vol.14 , pp. 1296-1302
    • Sarbassov, D.D.1
  • 6
    • 81455151255 scopus 로고    scopus 로고
    • The tuberous sclerosis complex
    • Crino P.B. The tuberous sclerosis complex. N. Engl. J. Med. 355 (2006) 1345-1356
    • (2006) N. Engl. J. Med. , vol.355 , pp. 1345-1356
    • Crino, P.B.1
  • 7
    • 0043127125 scopus 로고    scopus 로고
    • Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
    • Inoki K. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 1 (2003) 1829-1834
    • (2003) Genes Dev. , vol.1 , pp. 1829-1834
    • Inoki, K.1
  • 8
    • 0036632368 scopus 로고    scopus 로고
    • The phosphatidylinositol 3-kinase AKT pathway in human cancer
    • Vivanco I. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer 2 (2002) 489-501
    • (2002) Nat. Rev. Cancer , vol.2 , pp. 489-501
    • Vivanco, I.1
  • 9
    • 0034648765 scopus 로고    scopus 로고
    • Angiogenesis in cancer and other diseases
    • Carmeliet. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
    • (2000) Nature , vol.407 , pp. 249-257
    • Carmeliet1
  • 10
    • 33747488399 scopus 로고    scopus 로고
    • PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR
    • Bernardi R. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 442 (2006) 779-785
    • (2006) Nature , vol.442 , pp. 779-785
    • Bernardi, R.1
  • 11
    • 0033587146 scopus 로고    scopus 로고
    • The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
    • Maxwell P.H. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
    • (1999) Nature , vol.399 , pp. 271-275
    • Maxwell, P.H.1
  • 12
    • 33846080045 scopus 로고    scopus 로고
    • Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2
    • Li W. Hypoxia-induced endothelial proliferation requires both mTORC1 and mTORC2. Circ. Res. 100 (2007) 79-87
    • (2007) Circ. Res. , vol.100 , pp. 79-87
    • Li, W.1
  • 13
    • 0016724057 scopus 로고
    • Rapamycin (AY-22.989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete ans isolation of the active principle
    • Vezina C. Rapamycin (AY-22.989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete ans isolation of the active principle. J. Antibiot. (Tokyo) 28 (1975) 721-726
    • (1975) J. Antibiot. (Tokyo) , vol.28 , pp. 721-726
    • Vezina, C.1
  • 14
    • 27644436740 scopus 로고    scopus 로고
    • Maintenance immunosuppression with target of rapamycin inhibitors is associated with a reduced incidence of the de novo malignancies
    • Kauffman H.M. Maintenance immunosuppression with target of rapamycin inhibitors is associated with a reduced incidence of the de novo malignancies. Transplantation 80 (2005) 883-889
    • (2005) Transplantation , vol.80 , pp. 883-889
    • Kauffman, H.M.1
  • 15
    • 0036174289 scopus 로고    scopus 로고
    • Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
    • Guba M. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8 (2002) 128-135
    • (2002) Nat. Med. , vol.8 , pp. 128-135
    • Guba, M.1
  • 16
    • 20144367584 scopus 로고    scopus 로고
    • Sirolimus for Kaposi's sarcoma in renal-transplant recipients
    • Stallone G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N. Engl. J. Med. 31 (2005) 1317-1323
    • (2005) N. Engl. J. Med. , vol.31 , pp. 1317-1323
    • Stallone, G.1
  • 17
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • Hudes G. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356 (2007) 2271-2281
    • (2007) N. Engl. J. Med. , vol.356 , pp. 2271-2281
    • Hudes, G.1
  • 18
    • 2942735384 scopus 로고    scopus 로고
    • Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
    • Raymond E. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 22 (2004) 2336-2347
    • (2004) J. Clin. Oncol. , vol.22 , pp. 2336-2347
    • Raymond, E.1
  • 19
    • 33750321673 scopus 로고    scopus 로고
    • A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer
    • Hidalgo M. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin. Cancer Res. 12 (2006) 5755-5763
    • (2006) Clin. Cancer Res. , vol.12 , pp. 5755-5763
    • Hidalgo, M.1
  • 20
    • 23944439945 scopus 로고    scopus 로고
    • Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
    • Chan S. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J. Clin. Oncol. 23 (2005) 5314-5322
    • (2005) J. Clin. Oncol. , vol.23 , pp. 5314-5322
    • Chan, S.1
  • 21
    • 34548528069 scopus 로고    scopus 로고
    • Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma
    • Motzer R.J. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J. Clin. Oncol. 25 (2007) 3958-3964
    • (2007) J. Clin. Oncol. , vol.25 , pp. 3958-3964
    • Motzer, R.J.1
  • 22
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • Motzer R.J. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356 (2007) 115-124
    • (2007) N. Engl. J. Med. , vol.356 , pp. 115-124
    • Motzer, R.J.1
  • 23
    • 0034790016 scopus 로고    scopus 로고
    • mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer
    • Yu K. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer 8 (2001) 249-258
    • (2001) Endocr. Relat. Cancer , vol.8 , pp. 249-258
    • Yu, K.1
  • 24
    • 23944481410 scopus 로고    scopus 로고
    • Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
    • Witzig T.E. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J. Clin. Oncol. 10 (2005) 5347-5356
    • (2005) J. Clin. Oncol. , vol.10 , pp. 5347-5356
    • Witzig, T.E.1
  • 25
    • 33847180901 scopus 로고    scopus 로고
    • Endometrial carcinoma: pathology and genetics
    • Prat J. Endometrial carcinoma: pathology and genetics. Pathology 39 (2007) 72-87
    • (2007) Pathology , vol.39 , pp. 72-87
    • Prat, J.1
  • 26
    • 16644393813 scopus 로고    scopus 로고
    • Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression
    • Salvesen H.B. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int. J. Oncol. 25 (2004) 1615-1623
    • (2004) Int. J. Oncol. , vol.25 , pp. 1615-1623
    • Salvesen, H.B.1
  • 27
    • 24744448247 scopus 로고    scopus 로고
    • PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma
    • Uegaki K. PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncol. Rep. 14 (2005) 389-392
    • (2005) Oncol. Rep. , vol.14 , pp. 389-392
    • Uegaki, K.1
  • 28
    • 33847415365 scopus 로고    scopus 로고
    • Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model
    • Milam M.R. Reduced progression of endometrial hyperplasia with oral mTOR inhibition in the Pten heterozygote murine model. Am. J. Obstet. Gynecol. 196 (2007) 247e1-247e5
    • (2007) Am. J. Obstet. Gynecol. , vol.196
    • Milam, M.R.1
  • 29
    • 33750271928 scopus 로고    scopus 로고
    • Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCIC IND 160
    • (abstract 3003)
    • Oza A.M. Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCIC IND 160. Proc. Am. Soc. Clin. Oncol. 24 (2005) (abstract 3003)
    • (2005) Proc. Am. Soc. Clin. Oncol. , vol.24
    • Oza, A.M.1
  • 30
    • 34447343798 scopus 로고    scopus 로고
    • Lessons learned in the development of targeted therapy for malignant gliomas
    • Omuro. Lessons learned in the development of targeted therapy for malignant gliomas. Mol. Cancer Ther. 6 (2007) 1909-1919
    • (2007) Mol. Cancer Ther. , vol.6 , pp. 1909-1919
    • Omuro1
  • 31
    • 23944453425 scopus 로고    scopus 로고
    • Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study
    • Galanis E. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol. 23 (2005) 5294-5304
    • (2005) J. Clin. Oncol. , vol.23 , pp. 5294-5304
    • Galanis, E.1
  • 32
    • 21044431575 scopus 로고    scopus 로고
    • Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
    • Chang S.M. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs 23 (2005) 357-361
    • (2005) Invest. New Drugs , vol.23 , pp. 357-361
    • Chang, S.M.1
  • 33
    • 35848959875 scopus 로고    scopus 로고
    • A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500)
    • Pandya K.J. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J. Thorac. Oncol. 2 (2007) 1036-1041
    • (2007) J. Thorac. Oncol. , vol.2 , pp. 1036-1041
    • Pandya, K.J.1
  • 34
    • 33845938611 scopus 로고    scopus 로고
    • A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS)
    • (abstract 9504)
    • Okuno S.H. A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS). Proc. Am. Soc. Clin. Oncol. 24 (2006) (abstract 9504)
    • (2006) Proc. Am. Soc. Clin. Oncol. , vol.24
    • Okuno, S.H.1
  • 35
    • 33750510023 scopus 로고    scopus 로고
    • A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas
    • Duran I. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br. J. Cancer 6 (2006) 1148-1154
    • (2006) Br. J. Cancer , vol.6 , pp. 1148-1154
    • Duran I1
  • 36
    • 9144233506 scopus 로고    scopus 로고
    • Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells
    • Boulay A. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res. 1 (2004) 252-261
    • (2004) Cancer Res. , vol.1 , pp. 252-261
    • Boulay, A.1
  • 37
    • 33746651683 scopus 로고    scopus 로고
    • A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
    • (abstract 4530)
    • Amato R.J. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). Proc. Am. Soc. Clin. Oncol. (2006) 24 (abstract 4530)
    • (2006) Proc. Am. Soc. Clin. Oncol. , pp. 24
    • Amato, R.J.1
  • 38
    • 35548977012 scopus 로고    scopus 로고
    • A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC)
    • (abstract 5107)
    • Jac J. A phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). Proc. Am. Soc. Clin. Oncol. (2007) 25 (abstract 5107)
    • (2007) Proc. Am. Soc. Clin. Oncol. , pp. 25
    • Jac, J.1
  • 39
    • 46749158800 scopus 로고    scopus 로고
    • A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer
    • (abstract 3513)
    • Ellard S. A randomized phase II study of two different schedules of RAD001C in patients with recurrent/metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 25 (2007) (abstract 3513)
    • (2007) Proc. Am. Soc. Clin. Oncol. , vol.25
    • Ellard, S.1
  • 40
    • 33846569938 scopus 로고    scopus 로고
    • Targeting mammalian target of rapamycin (mTOR) for health and diseases
    • Tsang CK. Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov. Today 12 (2007) 112-124
    • (2007) Drug Discov. Today , vol.12 , pp. 112-124
    • Tsang CK1
  • 41
    • 33750238350 scopus 로고    scopus 로고
    • Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas
    • (abstract 9505)
    • Chawla S.P. Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. Proc. Am. Soc. Clin. Oncol. 24 (2006) (abstract 9505)
    • (2006) Proc. Am. Soc. Clin. Oncol. , vol.24
    • Chawla, S.P.1
  • 42
    • 37149033966 scopus 로고    scopus 로고
    • Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of phase II trial
    • (abstract 10076)
    • Chawla S.P. Survival results with AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas: update of phase II trial. Proc. Am. Soc. Clin. Oncol. 25 (2007) (abstract 10076)
    • (2007) Proc. Am. Soc. Clin. Oncol. , vol.25
    • Chawla, S.P.1
  • 43
    • 33646917622 scopus 로고    scopus 로고
    • Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor
    • (abstract 3033)
    • Rivera V.M. Pharmacodynamic study of skin biopsy specimens in patients (pts) with refractory or advanced malignancies following administration of AP23573, an mTOR inhibitor. Proc. Am. Soc. Clin. Oncol. 23 (2005) (abstract 3033)
    • (2005) Proc. Am. Soc. Clin. Oncol. , vol.23
    • Rivera, V.M.1
  • 44
    • 33645635326 scopus 로고    scopus 로고
    • A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies
    • (abstract 6631)
    • Feldman E. A phase 2 clinical trial of AP23573, an mTOR inhibitor, in patients with relapsed or refractory hematologic malignancies. Proc. Am. Soc. Clin. Oncol. 23 (2005) (abstract 6631)
    • (2005) Proc. Am. Soc. Clin. Oncol. , vol.23
    • Feldman, E.1
  • 45
    • 37149010753 scopus 로고    scopus 로고
    • A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer
    • (abstract 5516)
    • Colombo N. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. Proc. Am. Soc. Clin. Oncol. 25 (2007) (abstract 5516)
    • (2007) Proc. Am. Soc. Clin. Oncol. , vol.25
    • Colombo, N.1
  • 46
    • 46749117290 scopus 로고    scopus 로고
    • 18F]2-fluoro-desoxy-d-glucose (FDG) positron emission tomography (PET) scan
    • (abstract 9028)
    • 18F]2-fluoro-desoxy-d-glucose (FDG) positron emission tomography (PET) scan. Proc. Am. Soc. Clin. Oncol. 23 (2005) (abstract 9028)
    • (2005) Proc. Am. Soc. Clin. Oncol. , vol.23
    • Sankhala, K.1
  • 47
    • 0041662261 scopus 로고    scopus 로고
    • Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients
    • Peralba J.M. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin. Cancer Res. 9 (2003) 2887-2892
    • (2003) Clin. Cancer Res. , vol.9 , pp. 2887-2892
    • Peralba, J.M.1
  • 48
    • 35348858663 scopus 로고    scopus 로고
    • Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma
    • Cho D. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin. Genitourin Cancer 5 (2007) 379-385
    • (2007) Clin. Genitourin Cancer , vol.5 , pp. 379-385
    • Cho, D.1
  • 49
    • 0035744033 scopus 로고    scopus 로고
    • Mechanisms of resistance to rapamycins
    • Huang S. Mechanisms of resistance to rapamycins. Drug Resist. Updat. 4 (2002) 378-391
    • (2002) Drug Resist. Updat. , vol.4 , pp. 378-391
    • Huang S1
  • 50
    • 33947538050 scopus 로고    scopus 로고
    • Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
    • Wan X. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 22 (2007) 1932-1940
    • (2007) Oncogene , vol.22 , pp. 1932-1940
    • Wan, X.1
  • 51
    • 35348917266 scopus 로고    scopus 로고
    • Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency
    • Lu C.H. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin. Cancer Res. 1 (2007) 5883-5888
    • (2007) Clin. Cancer Res. , vol.1 , pp. 5883-5888
    • Lu, C.H.1
  • 52
    • 33745903146 scopus 로고    scopus 로고
    • Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells
    • Treeck O. Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol. Oncol. 102 (2006) 292-299
    • (2006) Gynecol. Oncol. , vol.102 , pp. 292-299
    • Treeck, O.1
  • 53
    • 33748530840 scopus 로고    scopus 로고
    • Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer
    • (abstract 564)
    • Carpenter J.T. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 23 (2005) (abstract 564)
    • (2005) Proc. Am. Soc. Clin. Oncol. , vol.23
    • Carpenter, J.T.1
  • 54
    • 33846404324 scopus 로고    scopus 로고
    • Prospective FDG-PET and CT assessment of discontinuation of erlotinib (E) or gefitinib (G) in patients with EGFR TKI sensitive non-small cell lung cancer (NSCLC) who subsequently progress radiographically on E or G ("acquired resistance") followed by re-initiation of E or G and the subsequent addition of everolimus (RAD001)
    • (abstract 7065)
    • Riely G.J. Prospective FDG-PET and CT assessment of discontinuation of erlotinib (E) or gefitinib (G) in patients with EGFR TKI sensitive non-small cell lung cancer (NSCLC) who subsequently progress radiographically on E or G ("acquired resistance") followed by re-initiation of E or G and the subsequent addition of everolimus (RAD001). Proc. Am. Soc. Clin. Oncol. 24 (2006) (abstract 7065)
    • (2006) Proc. Am. Soc. Clin. Oncol. , vol.24
    • Riely, G.J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.